These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32736262)

  • 1. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity.
    Lee JY; Park T; Hong E; Amatya R; Park KA; Park YH; Min KA; Jin M; Lee S; Hwang S; Roh GS; Shin MC
    Biomaterials; 2020 Oct; 257():120250. PubMed ID: 32736262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered long-acting Esculentin-2CHa(1-30) fusion protein with potential applicability for the treatment of NAFLD.
    Lee J; Amatya R; Kim KE; Park YH; Hong E; Djayanti K; Min KA; Roh GS; Shin MC
    J Control Release; 2024 Aug; 372():699-712. PubMed ID: 38925336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo.
    Xia J; Gao G; Zhang C; Ying J; Li J
    Eur J Pharm Sci; 2023 Jun; 185():106422. PubMed ID: 36906110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain.
    Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J
    Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein.
    Seijsing J; Lindborg M; Höidén-Guthenberg I; Bönisch H; Guneriusson E; Frejd FY; Abrahmsén L; Ekblad C; Löfblom J; Uhlén M; Gräslund T
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17110-5. PubMed ID: 25406323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring a novel long-acting glucagon-like peptide-1 receptor agonist built on the albumin-binding domain and XTEN scaffolds.
    Zhou Y; Li J; Gao G; Li Y; Zhang C
    Heliyon; 2024 Jan; 10(2):e24340. PubMed ID: 38293540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
    Zheng YC
    Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
    Cantante C; Lourenço S; Morais M; Leandro J; Gano L; Silva N; Leandro P; Serrano M; Henriques AO; Andre A; Cunha-Santos C; Fontes C; Correia JDG; Aires-da-Silva F; Goncalves J
    J Biotechnol; 2017 Jul; 253():23-33. PubMed ID: 28549690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving pharmacological activities of thrombopoietin mimetic peptide by genetic fusion to albumin-binding domain.
    Li D; Gao G; Zhu B; Ying J
    Biotechnol Lett; 2023 Apr; 45(4):439-448. PubMed ID: 36879168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fusion of an albumin-binding domain extends the half-life of immunotoxins.
    Guo R; Guo W; Cao L; Liu H; Liu J; Xu H; Huang W; Wang F; Hong Z
    Int J Pharm; 2016 Sep; 511(1):538-549. PubMed ID: 27457423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.
    Zhang J; Bodenko V; Larkina M; Bezverkhniaia E; Xu T; Liao Y; Abouzayed A; Plotnikov E; Tretyakova M; Yuldasheva F; Belousov MV; Orlova A; Tolmachev V; Gräslund T; Vorobyeva A
    J Control Release; 2024 Jun; 370():468-478. PubMed ID: 38697314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like Peptide 1 Conjugated to Recombinant Human Serum Albumin Variants with Modified Neonatal Fc Receptor Binding Properties. Impact on Molecular Structure and Half-Life.
    Bukrinski JT; Sønderby P; Antunes F; Andersen B; Schmidt EGW; Peters GHJ; Harris P
    Biochemistry; 2017 Sep; 56(36):4860-4870. PubMed ID: 28799326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
    Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
    Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.